Tag Archives: MACE

¿Llegó el momento de replantear a la aspirina como la elección en prevención secundaria de MACE?

Should Aspirin Be the Standard of Secondary Prevention of MACE?

Should Aspirin Be the Standard of Secondary Prevention of MACE?

Much has been published recently on short term dual antiplatelet therapy (DAPT) both in acute (ACS) and chronic coronary syndrome (CCS) as well as safety of P2Y12 inhibitor monotherapy. When discussing secondary prevention in patients with established coronary artery disease, aspirin (ASA) has been the preferred drug for the prevention of new atherothrombotic events.  This

ACC 2022

ACC 2022 – POISE-3: Tranexamic Acid, Bleeding and Cardiovascular Events in Non-Cardiac Surgeries

Tranexamic Acid is an antifibrinolytic which has been shown to reduce bleeding in orthopedic patients and cardiac surgery. But evidence for its use in non-cardiac surgery is still limited.  The aim of this study was to assess whether tranexamic acid reduces the incidence of bleeding events, which include life threatening bleeding, major bleeding, or bleeding

Los dispositivos Amplatzer y Figulla demuestran ser seguros para el cierre percutáneo del foramen oval permeable

Amplatzer and Figulla Devices Prove to Be Safe for Percutaneous Patent Foramen Ovale Closure

Courtesy of Dr. José Álvarez. In patients with presumed paradoxical embolism through a patent foramen ovale (PFO) who are at high risk of recurrent thromboembolic events, percutaneous PFO closure is an alternative to pharmacological treatment. This closure has been shown to be safe and feasible with different devices including various technologies based on an umbrella,

reserva fraccional de flujo

Post PCI FFR Reduces MACE

Original Title: Utilizing Post-Intervention Fractional Flow Reserve to Optimize Acute Results and the Relationship to Long-Term Outcomes Reference: Shiv K. Agarwal, et al. JACC Cardiovascular Intervention 2016;9:1022-31   Courtesy of Dr. Carlos Fava.   Fractional flow reserve has shown benefits and it is considered the gold standard to assess intermediate lesions (Class IA), but its